Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Bernstein analyst Lee Hambright has maintained an "Outperform" rating for DexCom (DXCM) and raised the price target from $84.00 to $86.00, representing a 2.38% increase. The company designs and commercializes continuous glucose monitoring systems for diabetic patients, with a focus on integrating with insulin pumps for automatic insulin delivery. The average target price for DXCM is $86.80, indicating a potential 29.16% upside from the current price of $67.21.

Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios